PL2120917T3 - Sposób na łagodzenie działań niepożądanych terapii kwasem retinowym i/lub ulepszanie skuteczności bez zakłócania skuteczności - Google Patents

Sposób na łagodzenie działań niepożądanych terapii kwasem retinowym i/lub ulepszanie skuteczności bez zakłócania skuteczności

Info

Publication number
PL2120917T3
PL2120917T3 PL08726182T PL08726182T PL2120917T3 PL 2120917 T3 PL2120917 T3 PL 2120917T3 PL 08726182 T PL08726182 T PL 08726182T PL 08726182 T PL08726182 T PL 08726182T PL 2120917 T3 PL2120917 T3 PL 2120917T3
Authority
PL
Poland
Prior art keywords
efficacy
interfering
side effects
retinoic acid
acid therapy
Prior art date
Application number
PL08726182T
Other languages
English (en)
Inventor
Elaine L Jacobson
Myron K Jacobson
Russell Coyle
Hyuntae Kim
Donna L Coyle
Original Assignee
Univ Kentucky Res Found
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kentucky Res Found, Univ Arizona filed Critical Univ Kentucky Res Found
Publication of PL2120917T3 publication Critical patent/PL2120917T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88—Two- or multipart kits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88—Two- or multipart kits
    • A61K2800/884—Sequential application

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
PL08726182T 2007-02-28 2008-02-27 Sposób na łagodzenie działań niepożądanych terapii kwasem retinowym i/lub ulepszanie skuteczności bez zakłócania skuteczności PL2120917T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90393707P 2007-02-28 2007-02-28
EP08726182.2A EP2120917B1 (en) 2007-02-28 2008-02-27 Method for alleviating side effects of retinoic acid therapy and/or improving efficacy without interfering with efficacy
PCT/US2008/002605 WO2008106177A2 (en) 2007-02-28 2008-02-27 Method for alleviating side effects of retinoic acid therapy and/or improving efficacy without interfering with efficacy

Publications (1)

Publication Number Publication Date
PL2120917T3 true PL2120917T3 (pl) 2014-09-30

Family

ID=39721805

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08726182T PL2120917T3 (pl) 2007-02-28 2008-02-27 Sposób na łagodzenie działań niepożądanych terapii kwasem retinowym i/lub ulepszanie skuteczności bez zakłócania skuteczności

Country Status (16)

Country Link
US (1) US9642845B2 (pl)
EP (1) EP2120917B1 (pl)
JP (1) JP5699414B2 (pl)
CN (1) CN101742916B (pl)
AU (1) AU2008219633B2 (pl)
CA (1) CA2679315C (pl)
DK (1) DK2120917T3 (pl)
ES (1) ES2458566T3 (pl)
HK (1) HK1143955A1 (pl)
IL (1) IL200598A (pl)
MX (1) MX2009009188A (pl)
NZ (1) NZ579416A (pl)
PL (1) PL2120917T3 (pl)
PT (1) PT2120917E (pl)
RU (2) RU2442577C2 (pl)
WO (1) WO2008106177A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383167B2 (en) 2011-03-08 2013-02-26 Elc Management, Llc Method for cosmetically treating caspase-14 deficiency
FR2975002B1 (fr) 2011-05-12 2020-08-14 Jean-Noel Thorel Procede de traitement cosmetique de la peau en deux etapes successives
US10076479B1 (en) 2018-05-08 2018-09-18 Avon Products, Inc. Methods for treating skin
AU2016226072B2 (en) * 2015-03-05 2021-07-01 Avon Products, Inc. Methods for treating skin
DE202021004224U1 (de) * 2020-05-06 2023-02-16 Mary Kay Inc. Kosmetikzusammensetzung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5939082A (en) * 1995-11-06 1999-08-17 The Procter & Gamble Company Methods of regulating skin appearance with vitamin B3 compound
DE69919403T2 (de) * 1998-12-01 2005-09-08 The University Of Kentucky Research Foundation Verwendung von nikotinsäurederivate zur behandlung von dna-schäden bei hautzellen
EP1274429B1 (en) * 2000-04-14 2008-05-14 Niadyne Corporation Topical formulations for the transdermal delivery of niacin prodrugs and methods of treating hyperlipidemia
WO2002067988A2 (en) * 2001-02-27 2002-09-06 The Regents Of The University Of Michigan Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth receptor
US6750234B2 (en) * 2001-03-08 2004-06-15 University Of Kentucky Research Foundation Methods for increasing leptin levels using nicotinic acid compounds
CN101217999A (zh) * 2005-07-08 2008-07-09 宝洁公司 用于哺乳动物皮肤和毛发美化的个人护理组合物及方法

Also Published As

Publication number Publication date
CA2679315C (en) 2013-06-25
IL200598A0 (en) 2010-05-17
US9642845B2 (en) 2017-05-09
AU2008219633B2 (en) 2011-05-26
MX2009009188A (es) 2010-03-26
HK1143955A1 (zh) 2011-01-21
CA2679315A1 (en) 2008-09-04
DK2120917T3 (da) 2014-04-07
RU2463046C2 (ru) 2012-10-10
RU2009135872A (ru) 2011-04-10
CN101742916B (zh) 2015-08-19
WO2008106177A3 (en) 2008-11-06
AU2008219633A1 (en) 2008-09-04
RU2442577C2 (ru) 2012-02-20
CN101742916A (zh) 2010-06-16
IL200598A (en) 2015-07-30
NZ579416A (en) 2011-07-29
EP2120917A2 (en) 2009-11-25
EP2120917A4 (en) 2011-09-14
RU2010128725A (ru) 2012-01-20
US20100173957A1 (en) 2010-07-08
EP2120917B1 (en) 2014-01-22
JP2010520202A (ja) 2010-06-10
PT2120917E (pt) 2014-04-24
JP5699414B2 (ja) 2015-04-08
WO2008106177A2 (en) 2008-09-04
ES2458566T3 (es) 2014-05-06

Similar Documents

Publication Publication Date Title
HK1245098A1 (zh) 治療慢性疼痛的方法
GB0912941D0 (en) Methods and composition for reduction of side effects of therapeutic treatments
EP2334315A4 (en) MEANS AND METHOD OF TREATMENT TREATMENT
WO2010042548A9 (en) Methods of treating inflammation
IL195615A0 (en) Methods and devices for treatment of cardiac valves
HK1162366A1 (en) Devices and methods for treating and or preventing diseases
EP2276394A4 (en) SYSTEM AND METHOD FOR TREATING AND PREVENTING LOSS OF VISUAL ACUITY
WO2011071995A9 (en) Compounds and methods of treating ocular disorders
EP2401561A4 (en) DEVICE AND METHOD FOR TREATMENT BY CRYOTHERAPY
WO2009155116A9 (en) Methods of reducing pain and inflammation
ZA201105284B (en) Visfatin therapeutic agents for the treatment of acne and other conditions
HK1143955A1 (zh) 減輕視黃酸治療副作用和/或改進療效而不干擾療效的方法
IL213703A0 (en) Compounds and methods for the treatment of pain and other diseases
EP2349469A4 (en) DEVICES AND METHOD FOR THE TREATMENT OF MYOCARDIAL DISEASES
GB2468424B (en) Methods and compositions for reduction of side effects of therapeutic treatments
AU2008906584A0 (en) Methods of treatment and agents useful for same
AU2008901249A0 (en) Method of treatment and uses therefor
GB0800556D0 (en) Method of treatment and treatment therefor
AU2008902365A0 (en) Methods for treating muscle disorders and improving muscle form
GB0803515D0 (en) Medicament and method of treatment
AU2008903259A0 (en) Method of treatment
AU2008902659A0 (en) Method of Treatment
AU2008900291A0 (en) Method of treatment
AU2008904356A0 (en) Method of Treatment
AU2008904478A0 (en) Method of treatment